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INTRODUCTION 
Synaptic plasticity is one of the main factors underlying brain plasticity, and it 
refers to the ability of brain tissue to adequately react and adapt to continuous 
endogenous and environmental changes. For cognitive processes, such as 
learning, memory, sense and consciousness, continuous activity-induced 
remodelling of neuronal circuits is mandatory (Albright et al., 2000; Purves and 
Andrews, 1997). Neural cell adhesion molecule (NCAM) and the polysialylated 
form of NCAM (PSA-NCAM) are molecules that participate in a broad range of 
biological processes, such as cell adhesion, synaptic plasticity, neurite 
outgrowth or migration (Kiryushko et al., 2003; Rønn et al, 2000). Recent 
studies have demonstrated that brain plasticity plays a role in emotional 
behaviour and memory formation. Indeed, different behavioural tests have 
demonstrated that complete deficiency in the NCAM protein in mice results in 
impaired cognitive behaviour: deficits in spatial learning and exploratory 
behaviour and also cognitive deficits in contextual and cued fear conditioning 
have been described.  
Several lines of evidence show that NCAM is the key-player in the 
regulation of brain plasticity and that dysfunction of NCAM may play an 
important role in the development of depression. Several molecules, including 
fibroblast growth factor receptor 1 (FGFR1), that have been shown to interact 
with NCAM may be involved in the development of mood-disorders.  
The aim of the present study was to explore the effect of reduction of 
NCAM/PSA-NCAM expression levels on the behavioural phenotype of mice 
and to illuminate the intracellular pathway responsible for the cognitive 
dysfunction in these mice and those implicated in their reduced ability to cope 
with stress. By using mice partially or completely deficient in NCAM/PSA-
NCAM, the main pathways and interaction partners of NCAM were studied. To 
clarify how alterations in the serotonergic system were implicated in the 
depression-like phenotype of these animals, the serotonin transporter (SERT), 
which is the main mechanism for the removal of serotonin from the synapse, 
was analysed. How disrupted cognitive abilities influence NCAM-deficient 
mice in the elevated plus-maze (EPM) test was also studied, as it has been 
shown that learning can occur during the EPM test session.  
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REVIEW OF THE LITERATURE 
1. Cell adhesion molecules 
The cell adhesion molecules (CAMs) are glycoproteins that are located on the 
external surface of the cell membrane. They are required for dynamic contact 
with other cells, i.e., to recognize and interact either with other CAMs or with 
proteins of the extracellular matrix (ECM). Cell adhesion is necessary for tissue 
formation, maintenance and functioning during development and adulthood. 
They have been grouped into four super-families consisting of the immuno-
globulins (Ig), cadherins, integrins and the selectins that are further subdivided 
into smaller subfamilies. Subfamilies of Ig CAMs in the nervous system have 
been categorized according to the number of Ig-like domains, the presence and 
number of fibronectin type III-like repeats, the mode of attachment to the cell 
membrane (Cunningham, 1995), and the presence of catalytic cytoplasmic 
domain. This study is focused on the functions of the neural cell adhesion 
molecule (NCAM) from the Ig superfamily. All proteins in this superfamily are 
characterized by the presence of a specific number of Ig-like domains and 
fibronectin type III repeats (reviewed in Crossin and Krushel, 2000), whereas 
the intracellular parts show a more diverse structure. 
 
 
2. Neural cell adhesion molecule (NCAM) 
Neural cell adhesion molecule (NCAM; also referred to as N-CAM, CD56 
and – originally – D2) was the first cell adhesion molecule from the Ig 
superfamily that was identified (Jørgensen and Bock, 1974; Rutishauser et al., 
1976) and characterized in detail (Cunningham et al., 1987). It has been 
reported that as many as 27 distinct NCAM isoforms can be generated via 
alternative RNA splicing (Cunningham et al., 1987). Neural cell adhesion 
molecule mediates homophilic (i.e., between two or more NCAMs) and 
heterophilic (i.e., between NCAM and another molecule) cell–cell interactions. 
NCAM is expressed in neurons, glial cells, heart and skeletal muscles. The 
highest expression level is found in the central and peripheral nervous systems 
(Rutishauser, 1991, 1993; Walsh and Doherty, 1991, 1997). 
 
 
3. Structure and localization of NCAM 
NCAM is encoded by a single Ncam1 gene that contains at least 19 exons, the 
primary transcript of which exhibits a complex pattern of alternative splicing 
(Jørgensen and Bock, 1974; Cunningham et al., 1987; Owens et al., 1987). The 
extracellular domain of all NCAM isoforms are composed of five regions at the 
amino terminus that are homologous to Ig domains (Ig I–V) and that are 
followed by two fibronectin type III repeats (Cunningham et al., 1987;  
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Figure 1A). The various isoforms of NCAM can be categorized, based on the 
size of their cytoplasmic tails and cell surface membrane association, into three 
main groups named for their approximate molecular weight (Figure 1B): 
NCAM-120 (120kD), NCAM-140 (140kD), and NCAM-180 (180kD) 
(Cunningham et al., 1983; Chuong and Edelman, 1984). NCAM-180 is a single-
pass transmembrane protein generated from exons 0–19; NCAM-140 differs 
from NCAM-180 only in exon 18 and it is also a transmembrane protein but has 
a considerably shorter cytoplasmic domain; NCAM-120 is a 
glycophosphatidylinositol (GPI)-anchored protein resulting from the 
transcription of exons 0–15. NCAM also exists in a secreted form that is 
produced when one of the small exons located between exons 12 and 13 is 
included in the mRNA. This small exon contains a stop codon and gives rise to 
a truncated form of the extracellular part of NCAM (Walmod et al., 2004). 
Soluble forms of NCAM can also be generated via enzymatic excision of 
NCAM-120 from its GPI anchor (He et al., 1986) or via proteolytic cleavage of 
the extracellular domain of NCAM molecules (Hinkle et al., 2006). Soluble 
NCAM was also found in cerebrospinal fluid by Jørgensen and Bock (1975). 
During early phases of embryogenesis, these proteins are expressed in cells 
from all three germ layers. Within the synaptic environment, all three NCAM 
isoforms have distinct expression profiles; NCAM-120 is expressed 
predominantly on glia rather than on neurons (Goodman, 1996; Kiss and 
Muller, 2001), NCAM-180 appears to be expressed exclusively on neurons, 
particularly at the postsynaptic side of synapses, whereas NCAM-140 can be 
found on both glial cells and neurons (Schachner, 1997). 
 
 
4. Polysialic acid (PSA) and  
polysialic acid linked NCAM (PSA-NCAM) 
Polysialic acid (PSA) is a long (up to 200 residues), linear homopolymer of  
α-2,8-sialic acid that is found in large amounts in mammalian brains (Finne, 
1982). The addition of PSA to NCAM is mediated by two Golgi-associated 
polysialyltransferases: ST8SiaII and ST8SiaIV (Eckhardt et al., 1995; Naka-
yama et al., 1995; Yoshida et al., 1995), of which ST8SiaII is dominant during 
development whereas ST8SiaIV persists at relatively high levels in the postnatal 
brain (Kojima et al., 1996; Ong et al., 1998). Both of these sialyltransferases can 
catalyse the transfer of α-2,3- or α-2,6-linked sialic acid onto NCAM without an 
initiator (Muhlenhoff et al., 1996; Kojima et al., 1996), and they are potentially 
involved in the biosynthesis of the PSA that is associated with NCAM in 
mammalian tissues. Furthermore, it has been reported that all three major 
NCAM isoforms (NCAM-120,-140, and, -180) can be modified by PSA, which 
attaches to two N-glycans located within the fifth immunoglobulin domain. 
Polysialic acid has a particularly large hydrated volume and a high density of 
negative charges and therefore occupies a much larger volume than NCAM 
4
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itself. Thus, the presence of PSA-NCAM reduces cell-to-cell and cell-to-
extracellular matrix adhesion (Rutishauser, 1996; 2008), enabling NCAM and 
PSA-NCAM to modulate synaptic plasticity (Dityatev et al., 2004). Besides 
modulating cell adhesion, it has been proposed that PSA may be required to 
enhance the sensitivity of neurons to some growth factors, for example, brain-
derived neurotrophic factor (BDNF, Vutskits et al., 2001). During embryonic 
development, the majority of NCAM exists in polysialylated form, thereby 
promoting cell migration, neurogenesis, axonal sprouting and synaptic plasticity 
(Brusés and Rutishauser, 2001). In the adult brain, cell–cell contacts are 
stabilized by weakly sialylated forms of NCAM and only areas that exhibit 
neurogenic capacity or high levels of plasticity contain PSA-NCAM (Bonfanti, 
2006). Recent data indicate that PSA-NCAM expression is important for the 
connectivity of interneurons, and it has been suggested that NCAM is the only 
carrier of PSA in cortical interneurons (Gómez-Climent et al., 2011). However, 
there is evidence that although NCAM is the preferred substrate for 
polysialyltransferases, NCAM is not the exclusive carrier of PSA. Other cell-
surface molecules, such as sodium channel alpha subunit (Zuber et al., 1992), 
neurolipin 2 (Curreli el al., 2007) and SynCAM (Galuska et al., 2010), also 
show detectable levels of polysialylation. However, the function of PSA in 
these molecules remains largely unclear. 
 
 
5. Homophilic and heterophilic interaction of NCAM  
5.1. Homophilic interactions 
NCAM has long been evidenced to interact in a homophilic trans fashion; 
NCAM molecules on one cell surface interact with NCAM molecules on the 
opposing cell surface (Rutishauser et al., 1982). NCAM has been found to be 
involved in cell surface recognition and can promote cell adhesion via a 
homophilic Ca2+-independent binding mechanism (Edelman, 1986). The first 
measurements of binding between NCAM Ig modules demonstrated binding 
between IgI and IgII modules to each other (Kiselyov et al. 1997; Atkins et al. 
1999). X-ray crystallography revealed homophilic binding between the IgI and 
IgIII domains (Soroka et al., 2003). It has also been shown that combined  
IgI-IgII modules interact with the same IgI-IgII modules of another NCAM 
molecule (Jensen et al., 1999). It has been demonstrated that interactions 
between IgI-IgII double modules is approximately 30 times more prevalent than 
between IgI-IgII single modules, and the interaction is not affected by the IgIII 
domain (Atkins et al., 1999; 2001). The IgI-IgII double structure model has 
been also further supported by crystallographic analysis (Kasper et al., 2000). 
Based on these structural and functional studies, which were performed by 
Soroka et al. (2003), a “double zipper model” has been proposed. It is specu-
lated that homophilic NCAM-mediated adhesion is a three-step process. The 
first step is cis-dimerization, the second step is formation of the “compact 
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zipper” (because this zipper is formed at a larger distance between opposing cell 
membranes than the “flat zipper” conformation), and the third step is the 
formation of a “compact, flat double zipper” resulting in a homophilic NCAM 





Figure 1. Molecular features of NCAM. (A) Schema illustrating the identifiable 
domains (left) and the post-translational modifications (right) found on the NCAM 
protein core. (B) The molecular structure of different NCAM isoforms. (C) The model 
for NCAM interactions. NCAM cis-dimers involve the interaction between IgI and IgII 
(red circle). NCAM trans-interactions require an initial formation of cis-dimers. Two 
kinds of interactions between NCAM molecules on opposing cell membranes are then 
possible (Soroka et al., 2003). The “flat zipper” interaction, illustrated in the picture, 
involves IgII and IgIII domains (green circle).  
ECD: extracellular domain; TMD: transmembrane domain; ICD: intracellular domain: IgI–V:  




5.2. Heterophilic interactions  
NCAM is capable of binding to a number of proteins on the cell surface in-
cluding CAMs and extracellular matrix molecules. For example, it has been 
shown that NCAM may interact with the L1 molecule in a cis-fashion, which 
triggers phosphorylation of tyrosine and serine residues in L1 (Heiland et al., 
1998). Additionally NCAM can also bind to another Ig-CAM: TAG-1/axonin-1, 
which was reported to bind to L1 in a cis-fashion (Malhotra et al., 1998), or to 
the adhesion molecule on glia, AMOG (Horstkorte et al., 1993). Furthermore, 
Dzhandzhugazyan and Bock (1993) have shown that the ATPase is tightly 
associated with NCAM and that ATP can bind directly to NCAM (Dzhand-
16 
zhugazyan and Bock, 1997). NCAM may also interact with some components 
of the extracellular matrix. Cole and Akeson (1989) characterized the NCAM 
heparin-binding domain and showed that it consisted of two basic regions 
between residues 150 and 166 within the Ig2 module (Cole et al., 1986; 
Herndon et al., 1999). It is reported that NCAM can also bind to collagen, most 
likely via heparin sulphate (Kiselyov et al., 1997). In chicken brains, it was 
demonstrated that NCAM colocalizes and copurifies with an abundant heparan 
sulfate proteoglycan (Burg et al., 1995), which is presumably bound to NCAM 
via heparin-binding sites localized to the first and second Ig modules (Cole and 
Akeson, 1989; Kiselyov et al., 1997; Burg et al., 1995). Several growth factor 
interactions with NCAM have also been demonstrated. The glial cell line-
derived neurotrophic factor (GDNF) and its receptor, the GPI-linked GDNF 
family receptor-α (GFRα) can both bind directly to NCAM (Paratcha et al., 
2003). These studies on GDNF–NCAM interactions demonstrated that NCAM-
mediated GDNF signalling leads to neurite outgrowth from embryonic 
hippocampal and cortical neurons (Paratcha et al., 2003). Interestingly, the 
binding of GDNF is independent of the presence of PSA on NCAM and does 
not interfere with homophilic NCAM-NCAM interactions. Binding of GFRα to 
NCAM inhibits homophilic NCAM-NCAM trans-interactions but may con-
currently potentiate the binding of GDNF to NCAM (Paratcha et al., 2003; 
Nielsen et al., 2009). Besides GDNF, NCAM also interacts with brain-derived 
neurotrophic factor (BDNF; Vutskits et al., 2001), platelet-derived growth 
factor (PDGF; Zhang et al., 2004), epidermal growth factor receptor (EGFR; 
Povlsen et al., 2008) and growth cone associated protein (GAP-43) (Meiri et al., 
1998). One of major interaction partners of NCAM is the fibroblast growth 
factor receptor 1 (FGFR1).  
 
 
6. NCAM/PSA-NCAM interactions with FGFR1 
Fibroblast growth factor receptors (FGFR1–FGFR4) are a family of trans-
membrane tyrosine kinases that signal via interactions with the family of 
fibroblast growth factors (FGF-1–FGF-23) (Itoh and Ornitz, 2004). The first 
evidence of an interaction between NCAM and FGFR was obtained by 
Williams et al. (1994a) and confirmed by other studies (Povlsen et al. 2003; 
Hinsby et al. 2004). It has been demonstrated that NCAM may bind directly to 
FGFR, which bears tyrosine kinase activity. Furthermore, NCAM-NCAM 
binding leads to the phosphorylation of FGFR (Saffell et al., 1997), which 
suggests that NCAM binds to FGFR and can directly or indirectly stimulate it. 
It was proposed on basis of surface plasmon resonance analysis that F3-I and 
F3-II modules of NCAM can bind the FGFR Ig-modules D2 and D3 (Kiselyov 
et al., 2003) directly. NCAM and FGFR1 have been studied extensively and the 
interaction between FGFR1 and NCAM is well characterized (Kiselyov, 2010). 
NCAM and FGFR1 has been demonstrated to be associated in several cell types 
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(Cavallaro et al., 2001; Francavilla et al., 2007) and to modulate various FGFR-
mediated neuronal functions (Hansen et al., 2010). Previous findings have 
shown that polysialylated NCAM is preferred for the activation of FGFR1 
(Kiselyov et al., 2005) and that ATP inhibits the interaction between NCAM 
and FGFR1 (Kiselyov et al., 2003). It has been shown that NCAM stimulation 
leads to the phosphorylation of FGFR1 with subsequent neurite outgrowth (via 
activation of the Ras-MAPK pathway), a process by which differentiating 
neurons extend axons and dendrites (Kolkova et al. 2000). Recent studies have 
shown a close association between NCAM and FGFR2 (Vesterlund et al., 2011) 
but the mechanism underlying NCAM-FGFR2 interactions and the role of this 
interaction remain unclear. Basic fibroblast growth factor (FGF-2) is important 
in the activation of FGFR1. FGF-2 is a heparin-binding basic protein that is the 
prototypic member of a family of 22 related proteins (Ornitz and Itoh, 2001). It 
has been demonstrated that FGF-2 exhibits high affinity with FGFR1 and 
FGFR2 (Frantl et al., 1993; Ibrahimi et al., 2004), and furthermore, it has been 
shown that FGF-2, as with NCAM, can activate the FGFR1 (Plotnikov et al., 
2000; Frinchi et al., 2008); however, NCAM activates FGFR signalling in a 
manner distinct from FGF-2 stimulation (Hinsby et al., 2004). 
 
 
7. NCAM/PSA-NCAM mediated  
intracellular signalling 
Soon after the discovery of NCAM, it was demonstrated that NCAM/PSA-
NCAM participates in a number of direct or indirect interactions with many 
intra- or extracellular molecules, and many downstream signal pathways are 
dependent on NCAM/PSA-NCAM-mediated cellular signalling. The neurite 
promotion properties demonstrated for NCAM were shown to be dependent 
upon homophilic interactions between corresponding molecules (Doherty and 
Walsh, 1996). This idea is supported by experiments that show that homophilic 
NCAM interactions are dependent on the mitogen activated protein kinase 
(MAPK) pathway (Kolkova et al. 2000). Furthermore, NCAM induces 
intracellular signalling that leads to the activation of MAPK and cyclic-AMP 
response-element binding protein (CREB), which are activated either by Rsk 
kinase or via MSK1 kinase (mitogen and stress-activated kinases), both of 
which are downstream of mitogen-activated protein kinases ERK1/2 (Schmid et 
al., 1999). Immunoprecipitation studies revealed an association between NCAM 
and non-receptor tyrosine kinases Fyn and focal adhesion kinase (FAK) (Beggs 
et al., 1997). The mechanism underlying the association of NCAM with Fyn 
likely depends on the binding of receptor protein tyrosine phosphatase-α 
(RPTPα) (Roskoski R, 2005). 
The interplay between NCAM and fibroblast growth factor receptor (FGFR) 
in neuronal cells mediates NCAM-dependent neurite outgrowth (Walsh and 
Doherty, 1997) and plays an important role in cell adhesion, cell migration, 
5 
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neural differentiation, synapse formation, and synaptic plasticity (Kiryushko et 
al., 2004; Sytnyk et al., 2004; Maness and Schachner, 2007). It was shown that 
NCAM can directly interact with FGFRs thereby inducing their auto-
phosphorylation (Kiselyov et al., 2003). The phosphorylated residues on the 
cytoplasmic part of FGFR dock with several proteins including the enzyme 
phospholipase Cγ (PLCγ), which becomes activated upon binding. The 
substrate of PLCγ is phosphatidylinositol 4,5-bisphosphate (PIP2), which is 
cleaved to generate the two second messengers inositol 1,4,5-trisphosphate (IP3) 
and diacylglycerol (DAG). IP3 diffuses through the cytosol and binds to 
intracellular Ca2+-channels, leading to the release of Ca2+ from intracellular 
stores and an increase in intracellular calcium concentrations [Ca2+]i. DAG 
remains a part of the plasma membrane and can either activate protein kinase C 
(PKC) or is converted by DAG lipase to 2-arachidonylglycerol (2-AG) and 
arachidonic acid (AA), the latter of which can induce various downstream 
signalling events (Walmod et al., 2004). It has also been demonstrated that AA 
may modulate specific Ca2+ channels located in the plasma membrane, thus 
triggering Ca2+ influx into the cytosol and subsequent induction of neurite out-
growth (Williams et al., 1994b). FGF-2, another FGFR1 activator, was shown 
to be mediated by 2-AG. It is thought that the addition of AA to cells may lead 
to an increased level of 2-AG and that addition of AA therefore indirectly 
stimulates 2-AG mediated signalling (Williams et al., 2003). However, the 
relative importance of AA and 2-AG for NCAM-mediated neuritogenesis 
remains unclear. Nevertheless, because NCAM can interact with GDNF and 
GFRα and thereby activate downstream signalling components including Fyn, 
FAK, and ERK1/2, it can also activate neurite outgrowth and cell migration in 
an FGFR independent manner (Paratcha et al., 2003).  
Ca2+-calmodulin-dependent protein kinase II (CaMKII) is another serine/ 
threonine protein kinase that associates with NCAM (Sytnyk et al., 2006). It has 
been shown that clustering of NCAM at the cell surface induces lipid raft–
dependent activation of CaMKIIα, which then phosphorylates RPTPα at two 
serine residues, which in turn leads to the activation of Fyn (Bodrikov et al., 
2005; 2008), and thus, this concurrence indicates an important role in the 
trifunctional interaction between NCAM, CaMKIIα, and RPTPα in lipid rafts. 
NCAM can also trigger phosphorylation of the transcription factor CREB, 
which is activated either by Rsk kinase or via MSK1 kinase, which are down-
stream of ERK1/2 kinases (Schmid et al., 1999). Activation of CREB has been 
proposed to also regulate synaptic plasticity, neuronal survival, neuronal 
maturation, and developmental plasticity (West et al., 2002; Deisseroth et al., 
2003). CREB can be phosphorylated on serine 133 by multiple kinases inclu-
ding protein kinase A (PKA), calcium/calmodulin dependent kinases (CaMKs), 
and MAPK. It has been proposed that PLCγ-mediated release of intracellular 
Ca2+ triggers CREB phosphorylation via activation of calcium/calmodulin-
dependent kinase IV (CaMKIV) (Finkbeiner et al., 1997; Minichiello et al., 
2002). The NCAM-mediated increase in intracellular Ca2+
 
can also lead to an 
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activation of CREB-phosphorylation via CaMKII because it has been shown 
that NCAM-FGFRs-mediated neuritogenesis can be blocked by CaMK-
inhibitors (Williams et al., 1995). 
NCAM-induced neuritogenesis can also be regulated via the cAMP/PKA 
pathway. This pathway may be involved in NCAM-mediated signal trans-
duction, leading to the activation of two transcription factors, CREB and c-Fos, 
which are downstream of PKA, because it has been shown that inhibitors of 
cAMP and PKA can selectively abolish NCAM-mediated axonal outgrowth 
(Jessen et al., 2001). 
One of the molecules reported to increase phosphorylation of Akt and CREB 
in adult hippocampal neural progenitor cells was FGF-2 (Peltier et al., 2007). 
Ditlevsen et al. (2008) supported this finding by showing that FGF-2 induces 
phosphorylation of Akt, ERK, and CREB but they also found that FGFR1 must 
be present during this processes. 
 
 
8. The roles of NCAM/PSA-NCAM  
in brain plasticity and cognition 
Brain plasticity or neuroplasticity refers to the ability of brain tissue to ade-
quately react and adapt to continuous endogenous and environmental changes. 
Synaptic plasticity is one of the main drivers of brain plasticity, and adhesion 
molecules are the most significant key players, providing stable connections 
between the cells and at the same time, remodelling synaptic networks. It has 
been proposed that for cognitive processes, such as learning, memory, sense and 
consciousness, continuous activity-induced remodelling of neuronal circuits is 
required (Albright et al., 2000; Purves and Andrews, 1997). NCAM participates 
in a broad range of these biological processes including cell adhesion, synaptic 
plasticity, neurite outgrowth or migration (Kiryushko et al., 2003; Rønn et al, 
2000; Muller et al., 1996; Rutishauser et al., 1976). The adhesive properties of 
NCAM are regulated by the addition of PSA (Rutishauser, 1996), which 
attenuates NCAM-mediated cell interactions and thereby creates plasticity in 
the position and movement of cells and/or their processes (Rutishauser, 1996 
and Brusés and Rutishauser, 2001). Indeed, removal of PSA by endosialidase-
N, an enzyme that specifically cleaves PSA, disturbs neuronal migration, axonal 
sprouting, branching and fasciculation (Durbec and Cremer, 2001; Yamamoto 
et al., 2000) and also synaptogenesis (Dityatev et al., 2004), synaptic plasticity 
(Becker et al., 1996; Muller et al., 1996) and spatial memory (Becker et al., 
1996). Previous studies suggested functions for NCAM in the fasciculation of 
axons to form bundles, such as the retinotectal mossy fiber projections (Rutis-
hauser, 1985; Cremer et al., 1997). Some data suggest that NCAM is involved 
in both early synaptogenesis and subsequent synaptic maturation (Sytnyk et al., 
2002). PSA-NCAM-mediated sensitization of neurons to BDNF is an important 
mechanism that has been shown to be important in neuronal network plasticity 
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and could contribute to cortical reorganization (Kiss et al., 2001; Vutskits et al., 
2001). It is assumed that the most important function of NCAM/PSA-NCAM is 
in the regulation of the dynamic balance between stability and plasticity of 
synaptic contacts. Brusés and Rutishauser (2001) showed that PSA-NCAM is 
primarily expressed on axons and dendrites prior to contact formation but that 
after the contacts are formed, the expression is rapidly down-regulated. This 
theory is supported by findings that expression of PSA and PSA-NCAM is 
highest during development (Seki and Arai, 1991; Cox et al., 2009) and that it is 
up-regulated in the adult brain by neuronal activity and during learning-induced 
neuroplasticity in the hippocampus (Murphy et al., 1996). 
There are several data that demonstrate that brain plasticity plays a role in 
emotional behaviour and memory formation. Learning and memory impair-
ments are associated with a number of psychiatric and neurological disorders, 
such as Alzheimer’s disease, schizophrenia, depression, Parkinson’s disease, 
learning disabilities, age-related cognitive decline and mental retardation. 
Several lines of evidence also link dysregulation of NCAM signalling with 
psychiatric disorders including schizophrenia, depression and Alzheimer’s 
disease (reviewed in Brennaman and Maness, 2008). It has been shown that 
disrupting NCAM function by ablation of NCAM impairs synaptic plasticity in 
the hippocampus in vitro and in vivo (Cremer et al., 1994, Arami et al., 1996; 
Bukalo et al., 2004; Stoenica et al., 2006), which can lead to several memory 
and learning deficits (Cremer et al., 1994, 1998; Arami et al., 1996; Bukalo et 
al., 2004). NCAM and PSA-NCAM have been proposed to be important 
regulators of the effects of acute intrinsic stress on memory consolidation (Bisaz 
et al., 2009) and diminished NCAM expression may be a critical vulnerability 
factor for the development of behavioural alterations induced by stress (Bisaz 
and Sandi, 2012). 
 
 
9. NCAM involvement in stress and mood disorders 
Accumulating evidence indicates that chronic stress or continuous elevated 
levels of glucocorticoids affects the functioning of NCAM and its polysialylated 
form, PSA-NCAM (Sandi, 2004). Exposure to stressful situations can reduce 
NCAM levels in the hippocampus and prefrontal cortex (Sandi et al., 2005). 
Several stress-based depression models, such as chronic restraint stress (Venero 
et al., 2002), social stress (Touyarot et al., 2004), early life stress (Tsoory et al., 
2008; Chocyk et al., 2010) and contextual fear conditioning (Merino et al., 
2000), induce downregulation of hippocampal NCAM. In contrast to the 
reduction in NCAM, chronic restrained stress is associated with increased 
corticosteroids and increased levels of the polysialylated form of NCAM in the 
hippocampus (Pham et al., 2003; Sandi, 2004). These changes correlate with 
decreased levels of BDNF, whereas treatment with antidepressants can increase 
the levels of both proteins (Varea et al., 2007a; Koponen et al., 2005). It is 
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thought that PSA-NCAM may bind to BDNF, resulting in the phosphorylation 
of its major receptor, tropomyosin-related kinase B (TrkB). Thus, the increased 
levels of PSA-NCAM may be a compensatory response to the lower levels of 
BDNF in the depressed hippocampus (Brennamann and Maness, 2008). This 
hypothesis may be supported by findings that show that the expression of 
BDNF and TrkB is decreased in the hippocampus of depressed individuals and 
this reduction can be reversed by antidepressants (Nibuya et al., 1995). 
Moreover, it has been demonstrated that BDNF can interact with serotonin (5-
hydroxytryptamine, 5-HT) at several levels (Martinowich and Lu, 2008), and 
serotonin influences neuronal circuits relevant for anxiety and depression 
(Lucki, 1998). Defects in BDNF can thus alter serotonergic function (Guiard et 
al., 2008), and a key role in serotonergic function is played by the 5-HT 
transporter (5-HTT or SERT), which terminates the action of 5-HT by 
facilitating its reuptake into the presynaptic terminal (Blakely et al., 1994). 
Remarkably, polymorphisms in the SERT gene have been associated with 
depression and other mood disorders (Heils et al., 1996; Caspi et al., 2003).  
Major depression is believed to originate from an interaction of deficits in 
neuronal resiliency and in neuroprotective responses or from exacerbated 
functioning of deleterious pathways that eventually lead to neuronal dysfunction 
and psychopathology (Duman, 2009). Several studies have described opposing 
actions of chronic stress and antidepressant treatment on neuronal structural 
plasticity (Magarinos et al, 1999; Varea et al., 2007a), and a significant level of 
data implicate the hippocampus in the development of depression (Bremner 
2002; MacQueen et al., 2003; Janssen et al., 2004). It should be noted that 
patients diagnosed with major depression demonstrate morphological and 
functional alterations in the hippocampus (Bremner 2002; Cole et al., 2010) and 
impaired executive function (Frodl et al., 2006). Furthermore, an enhanced 
degradation of NCAM has been demonstrated in depressive patients (Tochigi et 
al., 2008), and a reduction in PSA-NCAM expression was found in the brains of 
patients diagnosed with major depression (Varea et al., 2007b; Varea et al., 
2012). Moreover, it has been demonstrated that the major interaction partner of 
NCAM, FGFR1, also plays a role in the development of mood disorders 
(Gaughran et al., 2006; Turner et al., 2011). Furthermore, administration of 
antidepressants increases the levels of FGFs and FGF-2 in hippocampal and 
cortical areas (Mallei et al., 2002; Bachis et al., 2008). It was also shown that 
acute or chronic administration of FGF-2 resulted in antidepressant-like effects, 
which was accompanied by an increase in FGFR1 levels, specifically in the 
dentate gyrus (Turner et al., 2008). 
Thus, several molecules that have been shown to interact with NCAM may 
be involved in the development of mood-disorders. NCAM is also a key-player 
in the regulation of brain plasticity, a dysfunction of which may play an 
important role in the development of depression. Thus, further study is required 
to determine how reduced NCAM/PSA-NCAM expression influences the 
development of mood disorders. 
6
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10. Mice with reduced expression of NCAM  
NCAM-deficient mice were originally generated by Cremer et al. (1994) using 
gene targeting in the C57B/6 strain. It was demonstrated that complete NCAM 
knock-out resulted in almost complete loss of PSA, reduced brain weight, 
reduced olfactory bulb size and a reduced density of mossy fibres in the 
hippocampus (Cremer et al., 1994; Cremer et al., 1997). Homozygous mutants 
appeared fertile and healthy but their average weight was approximately 10% 
less than wild-type and heterozygous littermates (Cremer et al., 1994). 
However, the reduced size of the olfactory bulb in mutant mice did not affect 
their odour distinction, and their motor abilities were similar to controls 
(Cremer et al., 1994). It has been proposed that the reduction in size of the 
olfactory bulb is caused by the smaller size of the granular cell layer whereas all 
other structures in the olfactory bulb appear normal (Cremer et al., 1994). 
Morphological changes caused by NCAM deficiency have also been found in 
other structures in the brain. A slightly laminated organisation of the CA3 
region (Cremer et al., 1998), an enlarged rostal migratory pathway and 
hippocampal gliosis (Chazal et al., 2000) have been described. Constitutive loss 
of NCAM expression (gene knock-out) affects LTP in the CA3 region of the 
hippocampus, which may be related to the abnormal development of mossy 
fibre projections (Cremer et al., 1998). Synaptic plasticity in the dentate gyrus is 
NCAM glycoprotein- but not PSA-dependent (Stoenica et al., 2006), and 
studies have demonstrated that a deficiency in NCAM but not PSA-NCAM 
induces an impairment in LTP in the dentate gyrus (Eckhardt et al., 2000; 
Stoenica et al., 2006). It has also been described that although neuromuscular 
maturation occurred normally in NCAM-deficient mice (see also Moscoso et 
al., 1998), their neuromuscular junctions were smaller (Rafuse et al., 2000).  
Recent study has demonstrated that complete NCAM knock-out in mice 
leads to the reduced levels in CREB phosphorylation in brain regions that play 
important roles in spatial and aversive learning (in prefrontal/frontal cortex, 
hippocampus and basolateral nucleus of amygdala). This reduction was 
accompanied by reduced levels of phosphorylated CaMKII and CaMKIV in the 
prefrontal/frontal cortex and hippocampus (Aonurm-Helm et al., 2008). 
Furthermore, NCAM–/– mice showed reduced phosphorylation of the major 
NCAM interaction partner FGFR1 (Aonurm-Helm et al., 2010). Different 
behavioural tests showed that complete knock-out of the NCAM gene in mice 
resulted in impaired cognitive behaviour, specifically, deficits in spatial learning 
and exploratory behaviour (Cremer, 1994; Stork et al., 2000), and cognitive 
deficits in contextual and cued fear conditioning (Stork et al., 2000; Senkov et 
al., 2006) are also described. Additionally, these mice demonstrate increased 
inter-male aggression (Stork et al., 1997) and anxiety-like behaviour (Stork et 
al., 1999). However, the impaired intracellular pathways underlying the 
cognitive dysfunction and those involved in the reduced ability to cope with 
stress remain unclear.  
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In the experiments of Stork et al. (1999), the anxiety-like behaviour was 
evidenced by an increased preference for the dark compartment in the light/dark 
avoidance test. This behaviour was accompanied with altered 5-HT1A response 
of NCAM-deficient mice, which supports the idea of a functional disturbance in 
the serotonergic system involved in their abnormal anxiety-like and aggressive 
behaviour (Stork et al., 1999). However, NCAM-deficient mice show normal 
synthesis and metabolism of 5-HT, and no significant alteration in the expres-
sion of 5-HT1A binding sites was detected in any brain area of NCAM–/– mice 
studied including in the dorsal raphe nucleus, frontal cortex, hippocampus, and 
amygdala (Stork et al., 1999).  
It has been shown that the major mechanism of terminating 5-HT neuro-
transmission is the reuptake of 5-HT by SERT, which absorbs extracellular  
5-HT into the cytoplasm (Blakely et al., 1994). Therefore, the activity of SERT 
has an important influence on the extracellular 5-HT concentration. Hence, 
more studies must be conducted to clarify the role of NCAM in 5-HT receptor 
signalling and to define the molecular and neural mechanisms involved in this 
process.  
Contrary to the results of the light/dark avoidance test, in the elevated plus-
maze test (EPM), NCAM-deficient mice demonstrated an increased preference 
for open arms, which is indicative of anxiolytic-like behaviour (Stork, et al., 
1999, 2000). Thus, it appeared that the performance of NCAM-deficient mice in 
tests of anxiety was dependent on the test employed. As accumulating data has 
shown that learning can occur during the EPM test session (Calzavara et al., 
2004; Calzavara, et al., 2005; Carobrez and Bertoglio, 2005; Bertoglio et al., 
2006), it is likely that the impaired learning and memory of NCAM-deficient 
mice could influence EPM test results.  
Interestingly, it has been shown that mice with a partial reduction in NCAM 
expression (NCAM+/–) display increased anxiety and inter-male aggression and 
a post-aggression test increase in corticosterone plasma concentration, similar to 
NCAM–/– mice (Stork et al., 1997, 1999). These data suggest that even a partial 
reduction in NCAM protein may cause alterations in behavioural phenotype. 
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THE AIMS OF THE STUDY 
The aims of the present study were: 
1. To assess how partial or complete deficiency of NCAM in mice affects their 
phenotype; 
2. To detect and measure how complete deficiency of NCAM influences the 
neuronal activity in the brain regions that are involved in memory functions; 
3. To determine how impaired cognition due to complete deficiency of NCAM 
affected behaviour of mice in the elevated plus-maze task; 
4. To determine how partial or complete deficiency of NCAM affected NCAM-
related pathways; 
5. To determine whether deficiency of NCAM affected an important compo-
nent of the serotonergic system – the serotonin transporter (SERT). 
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MATERIALS AND METHODS 
1. Subjects and drug treatment 
All experiments were performed in accordance with the guidelines established 
in the Principles of Laboratory Animal Care (Directive 86⁄609⁄EEC), and 
procedures were conducted in compliance with Estonian Law of Animal 
Protection and upon approval of the protocol nr. 117 by the Licensing 
Committee of Animal Experiments at the Estonian Ministry of Agriculture. All 
efforts were made to minimize the number of animals and their suffering. All 
experiments were performed by individuals who held an appropriate licence. 
The NCAM-deficient mice were originally generated by Cremer et al. (1994). 
The wild-type, NCAM+/– and NCAM–/– mice used for this study were 
obtained by crossing C57BL⁄6-Ncam tm1Cgn+⁄– heterozygous mice, which 
were purchased from Jackson Laboratories (Maine, USA). F5-generation 
NCAM+/– mice, NCAM–/– mice and their wild-type littermates, aged 2–4 
months and with an average weight of 23.5 g, were used. All animals were 
housed under standard housing conditions as follows: the mice were group-
housed (five or six mice per cage) using a 12 h light-dark cycle (lights on at 
9.00/lights off at 21.00). All mice had free access to food and water. The anti-
depressant used in the experiments was amitriptyline (Tocris Bioscience, UK), 




2. Behavioural testing 
2.1. General locomotor activity 
Locomotor activity was examined in a rectangular wooden cage (50 cm × 50 cm 
× 50 cm, L × W × H), which was illuminated uniformly with dim lighting. A 
light-sensitive video camera, connected to a computer, was mounted 1 m above 
the cage. The locomotor activity of an animal was monitored and analysed 




2.2. The elevated plus-maze test 
The EPM was made of metal and black plastic and the apparatus consisted of 
two opposite open arms (45 cm × 10 cm) without sidewalls and two enclosed 
arms (45 cm × 10 cm × 30 cm) with sides and end walls, all extending from a 
central square (10 cm × 10 cm). The maze was elevated to a height of 60 cm 
above the floor and placed in a dimly lit room (8 lux as measured at the centre 
of the maze). At the onset of the test, the animals (n=10 in each group) were 
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placed in the centre of the EPM facing towards an open arm and the 
experimenter recorded the number of open- and closed-arm entries and the time 
spent in either type of the arms, during a 5-min test period. An entry was 
counted when an animal placed all four paws in an arm. The maze was cleaned 
using 5% ethanol solution and water after each trial. All experiments were also 
video-recorded and analysed later for activity per minute. In addition to minute-
by-minute scoring, a test/retest protocol was used. Twenty-four hours after the 
first trial (Trial 1), a second trial was performed (Trial 2). All tests were 
performed at the same time of the day, between 11.00 and 14.00, and with the 
same experimenter. The percentage of entries into open arms out of total arm 
entries and the percentage of time spent in the open arms were used as measures 
of anxiety. In addition, the total number of entries was scored and used as a 
measure of locomotor activity.  
 
 
2.3. Object-recognition test 
The object-recognition task took place in a 50 cm × 50 cm × 50 cm (L × W × H) 
open field, made of brown wood, located in a testing room that was dimly 
(approximately 60 lux in the test arena) lit. The objects chosen were porcelain 
cups of different shapes and sizes; these objects were sufficiently heavy that the 
mice did not move them. All objects had similar textures and colours but 
distinctive shapes. For testing, each animal (n=7 per group) was first habituated 
by allowing it to freely explore the open field for 5 min. No objects were placed 
in the box during the habituation session. Twenty-four hours after habituation, 
individual mice were trained by placing them into the field for 5 min, into 
which two identical objects (2 × A) were positioned in two adjacent corners, 10 
cm from the walls. The amount of time each mouse spent exploring both objects 
was recorded. Short-term memory (STM) and long-term memory (LTM) tests 
were performed at 2 h and 24 h after training, respectively. In both tests, the 
mice explored the open field for 5 min in the presence of one familiar (A) and 
one novel (B for STM or C for LTM) object and the time the mice spent 
exploring the objects was recorded. A preference ratio for each mouse was 
expressed as a ratio of the amount of time spent exploring the new (B or C) 
object (Tnew ×100)/(TA + Tnew), where TA and Tnew are the times spent 
exploring the familiar object A and the novel object B or C, respectively. 
Between trials, the objects were cleaned using 5% ethanol solution. Exploration 
was defined as sniffing or touching the object with the nose and/or forepaws. 
The time spent exploring each object was recorded manually with a stop-watch 






2.4. Fear conditioning and extinction 
The contextual fear-memory test and contextual fear-extinction test in wild-
type, NCAM+/– and NCAM–/– mice were performed. For fear conditioning, an 
experimental chamber of 22 cm × 22 cm × 35 cm (L × W × H) was used. The 
box was made of transparent plastic. The floor was made of stainless steel rods 
that were designed for mice and that were connected to a scrambled shock 
generator (TSE Systems, Germany). The chamber contained a speaker that 
emitted audible tones. 
The chamber was housed inside a larger noise-attenuating box, and a built-in 
ventilation fan provided background noise. After each trial, the chamber was 
cleaned using 5% ethanol solution. On the training day, each mouse (n=8 per 
group) was allowed to freely explore the conditioning chamber during a 3-min 
contextual pre-exposure session. Following habituation, three conditioned 
stimulus (CS)/unconditioned stimulus (US) pairings were performed, with 
1 min intervals between pairs. The CS was an 85 db, 2800 Hz, 20 s tone, and 
the unconditioned stimulus was a scrambled foot shock of 0.70 mA, presented 
during the last 2 s of the CS. Freezing was defined as the absence of any move-
ment other than that due to respiration. A contextual fear-retention session was 
performed 24 h after the training session (day 1). Animals were placed into the 
conditioning context for 3 min in the absence of tone and shock and the 
duration of freezing was measured. Extinction tests began on the second day 
and consisted of daily 3-min re-exposures of mice to the conditioning context in 
the absence of shock over 6 consecutive days. Each session served as the con-
textual memory test. Twenty-four hours after the end of the extinction sessions 
(day 8), a tone-dependent memory recall test was performed by exposing mice 
to tone for 3 min in a novel context (Tronson et al., 2008). This test was 
performed to exclude nonspecific effects of the manipulations on freezing to a 
nonextinguished conditioned stimulus (tone). Freezing, characterised by a lack 
of movement other than respiration and heart-beat, was used as an indicator of 
learning. Total freezing time was scored manually and converted to a per-
centage (calculated as the percentage of time the mice spent freezing during the 
3-min context). All incidences of freezing behaviour were timed with a stop-
watch by an experimenter blinded to the genotypes of the animals. 
A separate group of animals from the wild-type and NCAM–/– group was 
used to measure and map neuronal activity in the brain regions that appeared to 
be involved in fear-conditioned memory functions. On the training day, these 
mice (wild-type, NCAM–/–; n=5 per group) received CS with US (shock) and 
24 h later were re-exposed to the CS and the duration (s) of freezing behaviour 
was measured. Two hours later each mouse was tested for their freezing 
response to the conditioned tone in a modified chamber. Six hours after re-
exposure to CS the brain tissue was harvested for immunohistochemical 
detection of FosB/FosB. For both genotypes, animals unexposed to tone fear 
conditioning were used as naïve controls. 
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2.5. Tail-suspension test (TST)  
The TST is similar to the forced-swim test and is based on the fact that mice 
suspended by the tail alternate between periods of struggle and immobility 
(reviewed in Cryan and Mombereau, 2004). Mice (n=8–10 per group) were 
suspended by the tail from a wooden beam, using adhesive tape at 1 cm from 
the tip of the tail. The total duration of immobility during the 6-min test period 
was measured. Immobility was defined as a complete lack of movement other 
than respiration. The immobility times were timed, using a stop-watch, by a 
trained observer who was blinded to the genotypes of the animals. 
To test the effect of antidepressant treatment on the behaviour of wild-type, 
NCAM+/– and NCAM–/– mice in the TST, separate groups of animals were 
divided into two subgroups (n=8–10 per group) and one of the following was 
administered i.p.: vehicle or amitriptyline (10 mg ⁄kg). Two hours later, the 
animals were subjected to the TST. 
 
 
2.6. Novelty-suppressed feeding test 
Mice were weighed and the chow was removed from their cage. Twenty-four 
hours after the removal of chow, mice were transferred to the testing room and 
placed in a clean holding cage where they were allowed to habituate for at least 
30 min. The testing apparatus consisted of a square wooden box (50 cm × 50 cm 
× 50 cm). The floor was covered with 2 cm of wooden bedding. A small piece 
of mouse chow was placed in the centre of the arena. At the start of the 
experiment, each mouse was placed in the corner of the testing area, and the 
time to the first feeding event was recorded. Animals that did not feed within 
this 5-min period were removed from all analyses. The latency to feed was 
timed, using a stop-watch, by a trained observer who was blinded to the 
genotypes of the animals. 
 
 
2.7. Sucrose-preference test 
To test for anhedonic behaviour, wild-type, NCAM+/– and NCAM–/– mice 
(n=6–7 per group) were subjected to a sucrose-preference test, which was 
conducted over 19 consecutive days. Each mouse was placed in a separate cage 
where it was given a free choice between two graduated bottles – one contained 
0.8% sucrose solution and the other tap water. To prevent place preference for 
drinking, the position of the bottles was alternated every 24 h. No food or water 
deprivation was applied prior to testing. The consumption of both liquids was 
estimated at the same time each day by measuring the level of liquid in each 
bottle. The sucrose preference was calculated as the amount of sucrose solution 
consumed as a percentage of the total liquid consumed.  
 
29 
2.8. Taste-aversion test 
Mice from all genotypes (n=6) were given a free choice between two graduated 
bottles, one containing a taste solution (100 mM HCl) and the other tap water. 
To prevent place preference for drinking, the position of the bottles was 
alternated every 24 h. The consumption of both liquids was estimated at the 
same time each day by measuring the level of liquid in each bottle. The taste 
aversion was calculated as the amount of taste solution consumed as a 
percentage of total liquid consumed. 
 
 
3. Protein quantitation 
3.1. Western blotting 
Adult (3 months old) wild-type, NCAM+/– and NCAM–/– mice (n=6 per 
group) were weighted and euthanized by decapitation. The brains were removed 
from the skulls, weighted and placed on ice. The hippocampi and prefrontal/ 
frontal cortex were quickly removed on ice in a +4°C room and immediately 
placed into liquid nitrogen and stored at –80°C until further processing. Tissues 
were lysed in 10 vol RIPA lysis buffer (20 mM Tris-HCl (pH 8.0), 137 mM 
NaCl, 10% glycerol, 1% NP-40, 2 mM EDTA) containing protease and 
phosphatase inhibitors, homogenised manually, incubated for 20 min on ice and 
then centrifuged (13,000 rpm for 20 min at +4°C).  
The following mono-or polyclonal primary antibodies were used: mouse 
anti-β-actin (clone AC-74, 1:10000, monoclonal antibody 107K4791; Sigma-
Aldrich Inc., MO, USA), mouse  anti-SERT (1:1000; Chemicon International 
Inc., US), goat anti-pCaMKIIα (Thr286, 1:800; sc-12886; lot: 63007), rabbit 
anti-CaMKII (M-176, 1:800; sc-9035; lot: H1407), rabbit anti-pCaMKIV 
(Thr196, 1:800; sc-28443-R; lot: H1806), goat anti-CaMKIV (M-20, 1:800; sc-
1546; lot: B1605), rabbit anti-pCREB-1 (1:1000; sc-101663; lot: D229), rabbit 
anti-CREB-1 (1:1000; sc-186; lot: 83374), mouse anti-FGF-2 (1:1000; sc-
136255; lot: I1309) and mouse anti-NCAM (1:1000; 556324; lot: 83374), goat 
anti-PSA-NCAM (1:1000; c0019; lot: 1107). The secondary antibodies used 
were: anti-goat IgG (HRP-conjugated, 1:400; cat no: PI-9500, Vector 
Laboratories, UK), anti-mouse IgG (HRP-conjugated), anti-mouse IgM (HRP-
conjugated) and anti-rabbit IgG (HRP-conjugated, 1:400; cat no: 32530, 31440 
and 32460, respectively, Pierce, US). All proteins of interest were measured and 
after stripping with buffer (10× stock; Millipore, CA, US), β-actin was 
measured on the same membrane. The membranes were incubated with ECL 
detection reagent (ECL, Amersham, UK) for 5 min to visualise the proteins and 
were then exposed to an autoradiography X-ray film (Amersham hyperfilm 
ECL, UK). The blots were probed for the proteins of interest and the density of 




The optical densities of the bands from the wild-type group were set to 100% 




To determine the expression of the FGF receptor-1 (FGFR1) and its phos-
phorylated form (pFGFR1) in the hippocampus of wild-type, NCAM+/– and 
NCAM–/– mice, initially, the total protein concentration of hippocampal lysates 
was determined using the Lowry protein assay (BioRad DC Protein Assay Kit, 
BioRad, USA; bovine serum albumin was used as the standard control). Equal 
amounts of total protein (0.5 mg) from the lysate were incubated overnight at 
+4°C with 1.5 µg of rabbit anti-FGFR1 antibody (1.5 µg/µl; ab10646; lot: 
622611), and the antigen-antibody complex was coupled with 25 µl of 50% 
solution of ProteinG Sepharose beads (GE Healthcare, USA) for 3 h at +4°C. 
The beads were centrifuged at 13,000 rpm for 5 min and washed three times 
using NP/T++ buffer (20 mM Tris-HCl (pH 6.8), 120 mM NaCl, 10% glycerol, 
1% NP40, 0.5% TritonX-100, 0.3% Na-dodecylsulphate) containing phos-
phatase and protease inhibitors. Following the final centrifugation step, the 
washing buffer was removed and the pellet was resuspended in equal volumes 
of Western blotting loading buffer (20 mM Tris-HCl (pH 6.8), 4% Na-
dodecylsulphate, 0.2% glycerol, 100 mM 1,4-dithiothreitol and bromophenol 
blue). The complexes were resolved by electrophoresis on 8% SDS-poly-
acrylamide gels. The proteins were transferred onto Hybond-P PVDF transfer 
membranes (Amersham Biosciences, UK) in 0.1 M Tris-base, 0.192 M glycine 
and 20% (v/v) methanol using an electrophoretic transfer system. The 
membranes were blocked with 0.1% (w/w) Tween-20/TBS containing 5% (w/v) 
non-fat dried milk powder for 1 h at room temperature. After blocking, the 
membranes were incubated overnight at +4°C with rabbit anti-pFGFR1 (Y645, 
1:5000; ab59194; lot: 464139) or rabbit anti-FGFR1 (1:5000; ab10646; lot: 
622611, both antibodies purchased from AbCam, USA), followed by an 
incubation with a secondary antibody (anti-rabbit HRP-conjugated antibody, 
1:2000, cat no: 32460, Pierce, USA) for 1 h at room temperature. The 
membranes were briefly incubated with ECL detection reagent (ECL, 
Amersham, RPN-2135, UK) to visualise the proteins, and they were then 
exposed to X-ray film. The blots were then analysed for optical density of each 
band using the QuantityOne 710 System (BioRad). The optical density ratios of 
the proteins were calculated and the ratio of phosphorylated protein to total 
protein was used for analysis. The ratio from the wild-type group was set to 






4.1. FosB/FosB immunohistochemistry  
To determine whether conditioned fear-related neuronal activity was induced in 
NCAM-deficient mice, a separate group of animals of both genotypes (wild-
type, NCAM–/–; n=5 each), which had been exposed to CS in the tone-induced 
fear-conditioning task, were used for FosB/FosB immunohistochemistry. In 
addition, naïve wild-type (n=5) and NCAM-deficient mice (n=5) were used for 
immunohistochemical determination of FosB/FosB and served as controls. 
Mice were deeply anaesthetized with chloral hydrate (300 mg/kg, i.p.) and 
transcardially perfused with 0.9% saline and then with 4% paraformaldehyde in 
phosphate buffered saline (PBS, 0.1 M, pH 7.4). After a post-fixation of the 
brain in paraformaldehyde/PBS solution for 24 h, 40-µm-thick sections were cut 
on a vibromicrotome (Leica VT1000S, Germany), placed in PBS and stored at 
+4°C until further processing. 
For FosB immunohistochemistry, free-floating sections were incubated in 
0.3% H2O2 in PBS for 30 min followed by incubation in a blocking solution for 
1 h. Blocking was followed by 24 h incubation at room temperature with rabbit 
polyclonal anti-FosB/ΔFosB (Santa Cruz Biotechnology Inc., Germany; 1:100 
dilution) diluted in blocking solution. Following washes in PBS, sections were 
incubated in biotinylated goat anti-rabbit antibody (Vector Laboratories, UK; 
1:200 dilution) diluted in blocking solution for 1 h. FosB-positive cells were 
visualized using the peroxidase method (ABC system and diaminobenzidine as 
the chromogen, Vector Laboratories, UK). The sections were dried, cleared with 
xylol and coverslipped with mounting medium (Vector Laboratories, UK).  
 
 
4.2. Quantification of FosB/FosB-positive cells 
FosB/FosB-positive nuclei were counted in the following brain areas 
according to demarcations provided by the Brain Mouse Atlas (Paxinos and 
Franklin, 2001): prefrontal cortex (PFC) and frontal cortex (FC), dentate gyrus 
of hippocampus (DG), basolateral nucleus of amygdala (BLA), basomedial 
nucleus of amygdala (BMA) and piriform cortex (Pir). For each structure, four 
random sections per animal were selected and positively stained nuclei were 
counted manually according to the optical fractionation method (West, 1993), 
and the number of counting frames in the delineated region was applied 
randomly by the CAST program (Olympus, Denmark). Counting was per-
formed using an Olympus BX-51 microscope. Immunoreactivity was expressed 
as the number of positive nuclei per 0.1 mm2 of brain region. The experimenter 





5. Data analysis and statistics 
All behavioural data are presented as the mean ±SEM. The immuno-
precipitation and western blotting data are expressed as a percentage of the 
wild-type ±SEM. Data were analysed using Prism software version 5.0 
(GraphPad Software Inc., San Diego,CA). Statistical analyses were performed 
using Student’s t-tests and one-way ANOVAs or two-way ANOVAs followed 
by the Bonferroni post-hoc test, where appropriate. A p-value of less than 0.05 
was considered significant. 
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Western blotting was performed to measure the quantity of NCAM isoforms 
and PSA-NCAM in hippocampal lysates from wild-type, NCAM+/– and 
NCAM–/– mice. There was a 50% reduction in the immunoreactivity of all 
NCAM isoforms and PSA-NCAM in the hippocampus of NCAM+/– mice 
compared with wild-type mice. The tissue from NCAM–/– mice did not 
demonstrate any NCAM or PSA-NCAM immunoreactivity (Figure 1). 
 
 
Figure 1. Expression of PSA-NCAM (panel A) and NCAM (180, 140 and 120 kD) 
proteins (panel B) in the hippocampi of wild-type, NCAM+/– and NCAM–/– mice. The 
data are expressed as a percentage of the wild-type ±SEM (n=6). *p<0.05; ***p<0.001 
compared with wild-type mice; ##p<0.01 compared with NCAM+/– mice (one-way 
ANOVA followed by Bonferroni post-hoc tests). 
RESULTS 
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1.1. Expression of PSA-NCAM and NCAM (180, 140, 120 kD) 
proteins in hippocampi of wild-type,  
NCAM+/− and NCAM–/– mice 
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To evaluate the ability to cope with stress and determine anhedonic behaviour in 
animals with a partial or complete deficiency of NCAM protein, we employed 
the tail-suspension test (TST), the novelty-suppressed feeding test and the 
sucrose-preference test. As shown in Figure 2A, the NCAM+⁄– and NCAM–/– 
mice spent a significantly longer time immobile in the tail-suspension test than 
their wild-type littermates. A one-way ANOVA demonstrated a highly signi-
ficant genotype effect: p<0.0001, F=10.57, d.f.=27 (n=8–10). Post-hoc analyses 
showed a significant increase in immobility time in both NCAM+/– (p<0.01) 
and NCAM–/– (p<0.001) mice (Figure 2A). To rule out the possibility that the 
longer period of immobility in the TST was due to impaired locomotion, we 
measured general locomotor activity. A one-way ANOVA revealed an effect of 
genotype: p<0.05, F=4.63, d.f.=28 (n=9–10). Post-hoc analyses revealed that 
NCAM–/– mice were more active (p<0.01) whereas NCAM+⁄– mice showed 
similar locomotor activity compared with wild-type animals (Figure 2B).  
Animals were next treated with the nonselective monoamine re-uptake 
inhibitor amitriptyline (10 mg/kg, i.p.) and tested for immobility in the TST. 
Two hours after administering the agent, the TST was performed. Amitriptyline 
significally reduced immobility time in all groups of animals (Table 1). 
However, a two-way ANOVA revealed an effect of genotype: (F2,50 = 15.80,  
p <0.0001), effect of amitriptyline (F1,50 = 51.62, p<0.0001) and an interaction 
between genotype and treatment (F2,50 = 3.75, p= 0.03). These data suggest 
that the effect of amitriptyline is more pronounced in mice with a deficiency in 
NCAM. 
The novelty-suppressed feeding test (NSF) is thought to assess emotional 
reactivity toward a new environment and induces competition between moti-
vational states (drive to eat vs. fear of venturing into the centre of the test 
arena). As shown in Figure 2C, the NCAM+⁄– and NCAM–/– mice demon-
strated a significantly longer latency to feed than their wild-type littermates 
(one-way ANOVA, p<0.05, F=3.90, d.f.=19, n=6–7). The enhanced effect of 
novelty on the suppression of feeding behaviour in NCAM+/– and NCAM–/– 
mice appears to be unrelated to food consumption as the mutant mice had 
similar body weights to their wild-type littermates (Figure 2D) and consumed 






1.2. Behaviour in mice with a partial or complete deficiency  
of NCAM protein 




Figure 2. Length of immobility in the tail suspension test (panel A), locomotor activity 
(panel B), latency to feed in novelty suppressed feeding test (panel C) and body weight 
(panel D) of wild-type, NCAM+/– and NCAM–/– mice. The data are expressed as mean 
±SEM (n=8–10). *p<0.05; **p<0.01; ***p<0.001 compared with wild-type mice (one-
way ANOVA, followed by Bonferroni post-hoc test). 
 
 
Table 1. The effect of acute administration of amitriptyline (10 mg/kg, i.p.) on the 
immobility time in the TST in wild-type, NCAM+/– and NCAM–/– mice. 
Group Vehicle Amitriptyline 
Reduction of 
immobility time (%) 
Wild-type 132.80 ± 10.600* 100.50 ± 6.74##0# 24.32 ± 7.34 
NCAM +/– 168.70 ± 3.78***0 123.00 ± 4.92###0 27.09 ± 3.12 
NCAM–/– 206.90 ± 8.81***0 126.90 ± 16.47### 38.66 ± 8.62 
The data are expressed as the mean ±SEM (n=8–10). **p<0.01 and ***p<0.001 compared with 
wild-type animals; #p<0.05, ##p<0.01 and ###p<0.001 compared with vehicle controls (two-way 
ANOVA followed by the Bonferroni post-hoc test). 
 
 
To test whether the ability to experience pleasure (anhedonia) was reduced in 
the mutant animals, wild-type, NCAM+/– and NCAM–/– mice were subjected 
to a sucrose-preference test, which is commonly used to detect motivational 
deficits (Strekalova et al., 2004; Rygula et al., 2005). The sucrose-preference 
test was performed over a period of 19 days. Control mice demonstrated a clear 
preference for the sucrose solution as it comprised ~75–80% of the total liquid 
consumed. In contrast, the NCAM+/– and NCAM–/– mice showed decreased 
preference for sucrose (Figure 3). A two-way ANOVA with repeated measures 
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revealed a significant effect of genotype in NCAM +/– and NCAM–/– mice 
(F1.216=16.33, p<0.01 and F1.144=58.13, p<0.0001, respectively) but no 
significant effect of time (F1.216=0.88 and F1.144=0.68, respectively) and no 
interaction (F1.216=1.27 and F1.144=0.16, respectively). Total fluid 
consumption did not differ between the wild-type and mutant mice (Figure 3).  
As the taste receptors in taste buds develop in the microenvironment 
supported by NCAM (Miura et al., 2005), the reduced preference for sucrose 
consumption may have resulted from a global impairment in taste cell and taste 
receptor development due to the reduced level of NCAM. To exclude this 
possibility, we performed a taste aversion test. The animals were given a free 
choice between water and 100 mM HCl. In preliminary experiments, we 
determined that wild-type animals began to avoid consuming bitter solutions 
containing HCl at concentrations of 100 mM, and therefore, we used this con-
centration of HCl to assess taste aversion in NCAM+/– or NCAM–/– mice. All 
groups demonstrated clear avoidance of the 100 mM HCl solution and 




Figure 3. Preference for sucrose and the total fluid consumption of NCAM+/– (panel A 
and B) and NCAM–/– (panel C and D) mice compared with wild-type mice in the 
sucrose-preference test. The data are expressed as the mean ±SEM (n=7). p<0.01, 




1.2.2. Object-recognition test 
To evaluate learning and memory functions in NCAM+/– and NCAM–/– mice, 
the object-recognition test was performed. In the object-recognition test, no 
group (NCAM+/–, NCAM–/– mice or their wild-type littermates) showed any 
significant preference for either of the two identical objects during the training 
phase (data not shown). During the test phase, for animals from all test-groups 
were presented with novel objects at 2 h (short-term memory, STM) and at 24 h 
(long-term memory, LTM) after the training phase. During STM and LTM 
phases, wild-type and NCAM+/– animals spent significantly more time 
exploring the new objects as shown by their preference ratio (Figure 4). No 
preferences for the novel object was observed for homozygote NCAM-deficient 
mice in either the STM or LTM test (Figure 4). 
 
 
Figure 4. Short-term memory- (STM) or long-term memory (LTM)-mediated 
exploratory preference (%) in the novel object-recognition test. The data are expressed 
as mean ±SEM (n=7). *p<0.05; **p<0.01 compared with wild-type animals; #p<0.05 




1.2.3. Fear conditioning and extinction 
To further explore cognitive functions and the ability to extinguish negative 
memories in NCAM+/– and NCAM–/– mice, the animals were subjected to 
tone and contextual fear-conditioning and contextual fear-extinction tests. In the 
tone and contextual fear-conditioning test, the time spent freezing at baseline 
prior to the test was similar between all genotypes (data not shown). Twenty-
four hours after fear conditioning (day 1), the animals were placed in the same 
context without tone or foot shock and the freezing behaviour was measured. A 
one-way ANOVA revealed a significant effect of genotype: p<0.05, F=4.41, 
d.f.=23 (n=8) and post-hoc analyses revealed that NCAM–/– mice showed 
significantly less freezing (p<0.05) compared with wild-type animals. The 
freezing time of NCAM+⁄– mice did not differ from that of wild-type mice 
10
38 
indicating that a partial deficiency in NCAM level does not affect contextual 
fear learning (Figure 5A). 
On the following day after testing animals for the retention of contextual fear 
memory, the extinctions sessions were initiated and they continued for 6 
consecutive days. Wild-type mice efficiently extinguished fear memory as 
demonstrated by the reduction in freezing time over the 6-day-testing period, 
whereas mice with a partial or full deficiency in NCAM protein showed 
significantly reduced extinction of contextual fear as revealed by the continued 
increased level of freezing behaviour during the extinction sessions (Figure 5A). 
A two-way ANOVA with repeated measures revealed a significant effect of 
genotype (F1.105=3.96, p<0.05), a significant effect of time (F1.105= 3.52, 
p<0.01) and no interactions (F1.105= 0.84, p<0.6). Following extinction 
training (on the 8th day), we performed a tone-induced fear recall test. Freezing 
behaviour was measured after exposing the mice to the tone in a novel context. 
The freezing time in the novel context prior to the recall test was similar 
between groups (Figure 5B). A one-way ANOVA revealed a significant effect 
of genotype (p<0.05, F=3.99, d.f.=23 (n=8)) in the tone-induced fear-recall test, 
and post-hoc analyses revealed that NCAM–/– mice showed significantly less 
freezing (p<0.05) compared with wild-type animals whereas NCAM+⁄– mice 
froze for similar periods of time compared with wild-type mice (Figure 5B). 
 
   
Figure 5. Contextual fear retention, contextual fear extinction (panel A) and tone-
induced fear recall (panel B) in wild-type, NCAM+/– and NCAM–/– mice. The data are 
expressed as the mean ±SEM (n=8). *p<0.05 compared with wild-type animals (one-
way ANOVA followed by a Bonferroni post-hoc test); #p<0.05 compared with wild-






2.1. Behaviour of NCAM-deficient mice in the EPM test 
We tested NCAM–/– mice for levels of anxiety using the plus-maze test. In this 
test, NCAM–/– mice demonstrated an increased percentage of entries into open 
arms and an increased percentage of time spent in the open arms of the plus-
maze during the 5 min test compared with wild-type animals (Figure 6). They 
also showed a higher number of total entries into the arms of the EPM. These 




Figure 6. Behaviour of NCAM-deficient mice and their wild-type littermates in the 
elevated plus-maze test. Percentage of entries into open arms (A); percentage of time 
spent in the open arms (B) and total number of entries (as a measure of locomotion, C) 
were scored. Data are expressed as the mean ±SEM (n=10).*p<0.05; **p<0.01; 
(Student’s t-test) compared with wild-type mice. 
 
 
2.2. Behaviour of NCAM-deficient mice in the EPM  
over time and following retesting 
Previous studies have suggested that a rapid learning of the aversive properties 
of the open arms in the EPM occurs during a 5 min test period that may affect 
the performance of animals (Carobrez and Bertoglio, 2005). To test such a 
possibility, we compared the percentage of entries into the open arms of the 
plus-maze on a minute-by-minute basis and found that in wild-type mice, the 
percentage of entries into the open arms was high during the first minute of the 
test but then dropped dramatically throughout the following four minutes of the 
5-min test (Figure 7). Thus, in wild-type mice, the test situation led to a gradual 
increase in avoidance behaviour and the decision to remain in the safer part of 
the maze, the enclosed arms, and suggests that some learning may have 
occurred during the testing session. In contrast, NCAM–/– mice demonstrated a 
stable and high percentage of entries throughout the 5 min test period (Figure 
7). No significant effect of the genotype on the total number of entries at each 
2. Influence of impaired cognition  
in NCAM–/– mice on their behaviour 
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time point during the 5-min session was found. Previous studies have 
demonstrated that re-exposure of rats to the EPM results in a dramatic reduction 
in percentage of entries into the open arms, which represents an avoidance-
learning response to open arms (Bertoglio et al., 2000). Therefore, in our experi-
ments, we re-exposed NCAM–/– mice and their wild-type littermates to the 
EPM. The results of this study are shown in Figure 8. A two-way ANOVA of 
the percentage of entries revealed a significant effect of genotype (F1.36=280.7, 
p<0.001) and a significant effect of trial (F1.36=10.0, p<0.01) but no significant 
interaction between genotype and trial (F1.36=3.8, p=0.059). Post-hoc analyses 
revealed that the re-exposure to the EPM reduced the percentage of entries only 
in wild-type mice and not in NCAM–/– mice (Figure 8). An analysis of the 
percentage of time spent in the open arms also demonstrated a significant effect 
of genotype (F1.36=280.7, p<0.001) and a significant effect of trial (F1.36=9.9, 
p<0.05) but no significant interaction between genotype and trial (F1.36=3.8, 
p=0.06). Re-exposure of the animals to the EPM did not affect the total number 
of entries to both open and closed arms compared with the first trial (Figure 8). 
However, there was a significant effect of genotype (F1.36=146.4, p<0.001) 
suggesting that NCAM–/– mice had higher locomotor activity compared with 
their wild-type littermates.  
 
 
Figure 7. Behaviour of NCAM-deficient mice and their wild-type littermates on the 
elevated plus-maze test on a minute-by-minute basis. The figure shows the percentage 
of entries into the open arms (left) and the number of total entries (right). Data are 
expressed as the mean ±SEM (n=10) *p<0.05; **p<0.01; (Student’s t-test) compared 
with wild-type mice. 
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Figure 8. Behaviour in the elevated plus-maze following re-testing of NCAM-deficient 
mice and their wild-type littermates. Percentage of entries into open arms (A); 
percentage of time spent in the open arms (B) and total number of entries (as a measure 
of locomotion, C) in test (Trial I) and re-test (Trial II) are shown. Data are expressed as 
the mean ±SEM (n=10).*p<0.05; **p <0.01; (two-way ANOVA followed by Bon-
ferroni post-hoc tests) comparing performances from Trial I and Trial II. 
 
 
2.3. FosB/FosB expression in wild-type  
and NCAM-deficient mice 
We next evaluated the distribution of FosB/FosB-positive cells in different 
brain regions of control mice and mice that had been exposed to tone fear-
conditioning. Mice with a complete deficiency of NCAM showed a signi-
11
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ficantly higher number of cells expressing FosB/FosB in the PFC, FC and 
BLA. A two way-ANOVA revealed a significant effect of genotype (PFC: 
p<0.01, F1.16=57.03; FC: p<0.01, F1.16=61.45; BLA: p<0.05, F1,16=7.336), a 
significant effect of tone fear conditioning (PFC: p<0.01, F1.16=124.1; FC: 
p<0.01, F1.16=110.0; BLA: p<0.05, F1,16=407.3) and a significant interaction 
between genotype and tone fear conditioning (PFC: p<0.01, F1.16=121.4; FC: 
p<0.01, F1.16=107.6; BLA: p<0.05, F1,16=473.3). Bonferroni post-hoc tests 
revealed an effect of tone fear conditioning on the number of FosB/FosB-
positive nuclei only in control mice and not in NCAM–/– mice (Figure 9, 
Table 2). There were no differences in the number of FosB/FosB-positive cells 
between wild-type and NCAM–/– mice in the BMA, DG or Pir (Figure 9, 
Table 2). Re-exposure of wild-type mice that had been conditioned for fear to 
the CS induced an increase in the number of FosB/FosB-positive cells in the 
PFC (p<0.001), FC (p<0.01) and BLA (p<0.001). Re-exposure of NCAM–/– 
mice to the conditioned stimulus did not affect FosB/FosB cell counts in any 




Figure 9. Representative microphotographs demonstrating FosB/FosB-positive cells 
in wild-type and NCAM-deficient mice 6 h after the presentation of CS in the tone fear-
conditioning task in the following brain regions: prefrontal cortex (PFC), frontal cortex 
(FC), dentate gyrus of hippocampus (DG), basolateral nucleus of amygdala (BLA), 
basomedial nucleus of amygdala (BMA) and piriform cortex (Pir). During training, 
mice received CS (tone) with US (shock) and 24 h later, they were tested for freezing 
behaviour, and six hours after re-exposure to CS, the brain tissue was harvested for 
immunohistochemical detection of FosB/FosB. Animals unexposed to fear con-
ditioning were used as naïve controls for both genotypes (magnification 100× for PFC, 
FC, BLA BMA and Pir; magnification 40× for DG). 
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Table 2. Number of FosB/FosB-positive cells in brain regions of NCAM-deficient 
and wild-type mice that had been exposed to the conditioned stimulus (CS) in the tone 
fear-conditioning task. 
 Wild-type NCAM –/– 
Brain region Control Conditioned Control Conditioned 
PFC 2.2 ± 0.2 20.1 ± 1.2 *** 5.0 ± 0.7 ### 5.1 ± 0.8 
FC 2.5 ± 0.8 20.6 ± 1.4 *** 04.7 ± 0.4 ### 4.8 ± 0.5 
DG 15.5 ± 2.6 15.2 ± 0.5 14.2 ± 2.2  15.2 ± 0.2 
BLA 7.5 ± 0.5 28.3 ± 0.4 *** 17.5 ± 0.7 #  17.4 ± 0.9 
BMA 18.9 ± 1.8 18.6 ± 0.2 17.9 ± 2.8  18.9 ± 0.2 
Pir 15.6 ± 1.4 15.4 ± 0.5 18.6 ± 3.2  19.1 ± 0.7 
The numbers of FosB/FosB-positive nuclei were counted in the following brain areas: prefrontal 
cortex (PFC) and frontal cortex (FC), dentate gyrus of hippocampus (DG), basolateral nucleus of 
amygdala (BLA), basomedial nucleus of amygdala (BMA) and piriform cortex (Pir). The data are 
expressed as the mean ±SEM of the number of positive cells per 0.1 mm2.  
Each group consisted of 5 mice. ***p0.001 compared with corresponding control; #p<0.05,  
###p<0.001 compared with wild-type mice from the control group (two-way ANOVA, 
Bonferroni post-hoc test). 
 
 
3. The effect of partial or complete deficiency of 
NCAM on NCAM-related pathways 
3.1. Reduced FGFR 1 phosphorylation and FGF-2 levels 
The FGFR1 is the major interaction partner for NCAM and PSA-NCAM 
(Doherty and Walsh, 1996; Kiselyov et al., 2003; reviewed in Kiselyov et al., 
2005). Therefore, it was of interest to determine whether a partial deficiency in 
NCAM proteins could lead to an alteration in FGFR1 phosphorylation. We 
measured the levels of total FGFR1 and its phosphorylated (pFGFR1) form in 
the hippocampus of NCAM+/– mice. NCAM–/– mice were again used for 
comparison in these experiments. Both the NCAM+/– and NCAM–/– mice 
demonstrated reduced levels of pFGFR1 in hippocampal tissue (one-way 
ANOVA, p<0.0001, F=22.96, d.f.=17, Figure 10). Homozygous NCAM–/– 
mice showed a much greater reduction (65–70%) in the basal phosphorylation 
level of FGFR1 than heterozygous NCAM+/– mice, which showed approxi-
mately 30% reduction from control levels (100%). No change in total FGFR1 
protein level was found in either NCAM+/– or NCAM–/– mice compared with 
control animals (Figure 10). 
As basic fibroblast growth factor 2 (FGF-2) is an important activator of 
FGFR1 phosphorylation (Plotnikov et al., 1999; Frinchi et al., 2008), we also 
measured the levels of FGF-2 in the hippocampus of NCAM+/– and NCAM–/– 
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mice and their wild-type littermates. The results revealed a significant increase 
in the levels of FGF-2 in both NCAM+/– and NCAM–/– mice compared with 
wild-type mice (Figure 10). 
 
 
Figure 10. The levels of phosphorylated and total FGFR1 proteins (panel A) and the 
levels of FGF-2 (panel B) in the hippocampi of wild-type, NCAM+/– and  
NCAM–/– mice. The data are expressed as a percentage of the wild-type ±SEM (n=6). 
*p<0.05; **p<0.01; ***p<0.001 compared with wild-type animals; ##p<0.01 compared 
with NCAM+/– mice (one-way ANOVA followed by Bonferroni post-hoc tests). 
 
 
3.2. The expression of phosphorylated CaMKII,  
CaMKIV and CREB 
A previous study (Aonurm-Helm et al., 2008) showed reduced levels of phos-
phorylated CREB and pCaMKII and pCaMKIV in the hippocampus of  
NCAM–/– mice, suggesting that this dysregulation may underlie the observed 
behavioural phenotype in NCAM–/– mice. Therefore, the levels of phos-
phorylated CaMKII, CaMKIV and CREB proteins in NCAM+/– mice were 
measured. NCAM–/– mice were again used for comparison in these experi-
ments. No differences in the immunoreactivity for total and phosphorylated 
CaMKII, CaMKIV or CREB were found in the hippocampi of NCAM+/– mice 
compared with wild-type mice (Figure 11). 
45 
 
Figure 11. The levels of phosphorylated and total CaMKII (panel A), CaMKIV (panel 
B) and CREB (panel C) in the hippocampi of wild-type, NCAM+/– and  
NCAM–/– mice. The data are expressed as a percentage of the wild-type ±SEM (n=6). 
*p<0.05 compared with wild-type animals; #p<0.01 compared with NCAM+/– mice 
(one-way ANOVA followed by Bonferroni post-hoc tests). 
 
 
4. The effect of partial or complete deficiency  
in NCAM on the serotonergric system  
The serotonergic system in the brain may be involved at several levels in 
depression pathways and depression-related behaviour (Lucki, 1998). The 5-HT 
transporter (SERT), which terminates the action of 5-HT by facilitating its 
reuptake into the presynaptic terminals (Blakely et al., 1994) plays a key role in 
serotonergic function. Therefore, it was of interest to determine whether SERT 






4.1. The expression of SERT 
Western blotting of SERT revealed two bands of 70 kD and 63–65 kD. Both 
bands were associated with SERT in the mouse brain, and both were 
significantly lower in the hippocampal and in prefrontal/frontal tissues of 
NCAM+/– and NCAM–/– mice compared to those in the wild-type littermates 
(in hippocampus: 70 kDa one-way ANOVA, p<0.0001, F=52.06, d.f.=18;  
63–65 kD one-way ANOVA, p<0.001, F=7.48, d.f.=18; in prefrontal/frontal 
cortex 70 kDa one-way ANOVA, p<0.0001, F=107.4, d.f.=18; 63–65 kD one-




Figure 12. The expression of SERT protein in the hippocampi (panel A) and 
prefrontal/frontal cortex (panel B) of wild-type, NCAM+/– and NCAM–/– mice. The 
data are expressed as a percentage of the wild-type ±SEM (n=6). *p<0.05; ***p<0.001 
compared with wild-type animals (one-way ANOVA followed by Bonferroni post-hoc 
tests). 
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The results of the present study show that mice with a partial deficiency of 
NCAM demonstrate increased immobility time in the TST, reduced sucrose 
preference in the sucrose preference test, increased latency in the novelty-
suppressed feeding test, and reduced extinction of contextual fear conditioning. 
The data shown here demonstrate that similar behavioural changes occur in 
homozygous knockout (NCAM–/–) mice. Our experiments also demonstrated 
that the known antidepressant amitriptyline decreased TST immobility times in 
NCAM +/– and NCAM–/– mice similar to wild-type mice. On the basis of the 
observed phenotype, we propose that these animals have increased stress-
induced anxiety, reduced ability to cope with stress, exhibit anhedonia and 
retain aversive emotional memories. Therefore, this behavioural phenotype 
could be described as a depression-related phenotype. 
In the TST test, immobility behaviour represents “behavioural despair”, 
which is based on observations that after initial escape-oriented movements, 
animals develop immobile postures when they are in an inescapable and 
stressful situation. Recent analysis has demonstrated that interventions that are 
known to cause susceptibility to depression or induce depression in humans also 
induce a depression-like effect (increased immobility) in the TST (reviewed in 
Cryan et al., 2005). Similarly, novelty-suppressed feeding behaviour reflects the 
reaction of animals to stress, and the face validity of this test has been 
demonstrated in several behavioural models of depression (Santarelli et al., 
2003; Uchida et al., 2011). In our experiments, all genotypes showed similar 
body weights and consumed the same amount of food in their home cages. 
Thus, we propose that the increased latency to consume food in the novel 
environment is related to levels of anxiety rather than changes in appetite. The 
sucrose-preference test has also been used extensively to measure anhedonia, 
which is a core symptom of depression. It should be noted that the reduced 
preference for sucrose consumption may have resulted from a global impair-
ment in the development of taste cells and receptors due to the deficiency in 
NCAM (Miura et al., 2005). We tested this latter possibility using bitter 
solutions containing HCl and demonstrated clear aversion in all wild-type, 
NCAM+/– and NCAM–/– animals. However, the possibility that taste receptor 
functions were affected by the reduction in NCAM and PSA-NCAM cannot be 
fully excluded.  
Another important finding in our study is that NCAM+/– mice were not 
impaired in the novel object-recognition task and fear conditioning task. In 
DISCUSSION 
1. Phenotype in mice with a partial or complete 
deficiency of NCAM protein 
1.1. The behavioural phenotype in mice with a partial  
or complete deficiency of NCAM protein 
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contrast, NCAM–/– mice demonstrated impaired memory retention in both 
tasks, which confirms previous studies (Stork et al., 2000; Senkov et al., 2006). 
Previous studies have demonstrated that acquisition of the context during 
contextual fear conditioning reflects associative memory functions (Wellman et 
al., 2007; Tronson et al., 2008). Rats with depression-like behaviour induced by 
prenatal stress (Green et al., 2011) or rats predisposed to learned helplessness 
(Shumake et al., 2005) showed reduced extinction of contextual fear. In 
contrast, animals with an antidepressant-like phenotype due to deficiency of 
ERK-1 kinase demonstrated enhanced extinction of contextual fear (Tronson et 
al., 2008). It appears that impaired fear extinction rather than the formation of 
fear memory is related to the depression-like state (Heldt et al., 2007; Wellman 
et al., 2007). In our experiments, both NCAM+/– and NCAM–/– demonstrated 
a reduced ability to extinguish contextual fear memory, and these data support 
our proposal that even partial reduction in NCAM proteins induces depression-
related behaviour without an impairment in memory acquisition and recall, at 
least in the cognitive tests that were employed in our study. Our data are in 
accordance with previous studies that demonstrated greater inter-male 
aggression with a post-test increase in corticosterone plasma concentrations in 
NCAM+/– mice (Stork et al., 1997, 1999).  
As NCAM–/– mice demonstrated impaired memory retention in the fear 
conditioning task, we used a separate group of animals to measure and map 
neuronal activity in the brain regions that are involved in memory functions. 
Abundant evidence suggests that the expression of families of immediate early 
genes, such as fos, fra, jun, krox and zif, is critical in changing the expression of 
genes important for memory formation (Dragunow et al., 1989; Hall et al., 
2001; Moller et al., 1994, Tischmayer and Grimm, 1999). In contrast to c-fos, 
which is transiently induced upon stimulation, FosB and its truncated form 
FosB, which is generated by alternative splicing of the FosB transcript, have 
prolonged induction characteristics and may be markers of chronic neuronal 
activation (Chen et al., 1997). Our experiments showed that re-exposure of 
wild-type mice to the CS (tone) induced expression of FosB/FosB in discrete 
neuronal populations within the PFC, FC and BLA and confirmed that 
FosB/FosB is also induced by memory retrieval in regions that are related to 
the formation of fear memories (Hall et al., 2001). In contrast, fear conditioning 
in NCAM–/– mice did not induce FosB/FosB expression in the BLA, PFC or 
FC. Furthermore, NCAM–/– mice, under basal conditions, demonstrated 
significantly higher numbers of FosB/FosB-positive cells in the BLA, PFC 
and FC compared with wild-type littermates. Assuming that FosB/FosB serve 
as relatively stable indicators of neuronal activity (Chen et al., 1997), our data 
suggest that in NCAM-deficient mice, structures involved in fear memory 
formation are constantly activated and this activation interferes with their ability 
to form new fear-related memories. 
Taken together, our data shows that homozygous NCAM knock-out mice 
demonstrate depression-like behaviour and altered cognitive functions. 
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Structures involved in fear memory formation seem to be hyperactive under 
basal conditions and this hyperactive state might interfere with ability of mice to 
form new memories. Mice with a partial reduction in NCAM protein levels 




2. Anxiety and cognition of NCAM–/– mice 
2.1. Learning and anxiety in NCAM–/– mice  
on the EPM task over time and in a test/retest paradigm 
Previous studies have shown that NCAM is required for the establishment of 
durable memories (Roullet et al., 1997) and that NCAM–/– mice show abnor-
malities in cell migration and synaptic plasticity, which leads to memory 
deficits and impaired learning ability (Cremer et al., 1994). Our data also 
demonstrates that NCAM–/– mice have impaired cognitive functions, as 
evidenced by the object-recognition and contextual and tone fear-conditioning 
tests. These results corroborate earlier studies in which NCAM–/– mice showed 
impaired learning (Cremer et al., 1994; Bukalo et al., 2004).  
Previous studies also demonstrated that deficiency in the NCAM gene results 
in increased inter-male aggression (Stork et al., 1997), depression-like be-
haviour (Aonurm-Helm et al., 2008) and anxiety-like behaviour (Stork et al., 
1999). In the experiments of Stork et al. (1999), the anxiety-like behaviour was 
evidenced by an increased preference for the dark compartment in the light/dark 
avoidance test (Stork et al., 1999). When the NCAM-deficient mice were 
exposed to the EPM, they demonstrated an increased preference for the open 
arms, which is suggestive of anxiolytic-like behaviour (Stork, et al., 1999, 
2000). Thus, it appeared that the performance of the NCAM-deficient mice in 
anxiety tests was dependent on the test employed. Our study also demonstrated 
some discrepancies when we measured anxiety-like behaviour in the novelty-
suppressed feeding test and the EPM. Novelty-suppressed feeding behaviour 
reflects the reaction of animals to stress, and it has been shown that the open-
field may induce moderate anxiety because the mice are placed in an open space 
without the possibility of escape (Prut and Belzug, 2003). In contrast, when 
NCAM-deficient mice were exposed to the EPM task they demonstrated an 
increased percentage of entries into and an increased percentage of time spent 
on the open arms of the EPM, which indicates anxiolytic-like behaviour. 
Because we used relative measures expressed as a percentage of entries and 
time, an increased exploratory behaviour, which indeed was observed in the 
NCAM-deficient mice, should have little if any impact on these relative 
measures. Previous studies using precise spatiotemporal analysis employing 
minute-by-minute analysis of the rodent’s behaviour in the EPM task demon-
strated a progressive increase in open arm avoidance during a 5 min session. 
These data demonstrated that during exposure to the EPM task, animals quickly 
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learn the aversive properties of the open arms, implying that learning can occur 
during the EPM session (Carobrez and Bertoglio, 2005). Therefore, we 
performed a minute-by-minute analysis of the behaviour of NCAM-deficient 
and wild-type littermates in the EPM task. Indeed, the analysis showed that the 
wild-type animals demonstrated a high percentage of entries onto the open arms 
only during the first minute of the EPM task. During the last four minutes, the 
percentage of entries onto the open arms declined considerably, suggesting that 
learning of the aversive properties of the open arms occurred. In contrast, the 
NCAM-deficient animals did not demonstrate any decline in the percentage of 
entries during the 5 min session. These findings show that the NCAM-deficient 
mice were unable to learn or to recognize the aversive properties of the open 
arms and that the observed anxiolytic-like behaviour was largely due to 
cognitive dysfunction. This hypothesis was further confirmed when the test/re-
test protocol of the EPM task was employed. In the second EPM trial, wild-type 
animals demonstrated clear avoidance of the open arms. This avoidance 
indicates that the mice acquired information during their exploration of the 
potentially dangerous areas of the maze during the first trial and that they 
consolidated this information and retrieved it during the second session. These 
data are consistent with those previously reported by others (File et al., 1990; 
Lister, 1990; Treit et al., 1993; Bertoglio and Carobrez, 2000). In contrast, when 
the NCAM-deficient mice were exposed to the test/re-test paradigm of the plus-
maze, no evidence of habituation was observed.  
In conclusion, the data obtained in this study show that the anxiolytic-like 
behaviour of NCAM-deficient mice in the EPM is largely due to their inability 
to recognize and learn the danger associated with the open arms. 
 
 
3. Altered NCAM-dependent signalling pathways  
in the brains of mice with partial or complete 
deficiency of the NCAM protein 
Previous in vitro and in vivo studies have shown that the major interaction 
partner of NCAM is FGFR1 and that a deficiency in NCAM causes reduced 
FGF receptor activation (Cavallaro et al., 2001; Kiselyov et al., 2003; reviewed 
in Kiselyov et al., 2005, Aonurm-Helm et al., 2010). We therefore measured the 
levels of FGFR1 protein and its phosphorylated form in the hippocampus of 
NCAM+/– mice and compared the results with those of NCAM–/– animals. In 
addition, we measured the levels of FGF-2 protein in these tissues. Our results 
demonstrated reduced levels of FGFR1 phosphorylation in both mutant 
genotypes without any changes in the total level of the FGF receptor protein. 
However, it should be noted that the decrease in phosphorylated FGFR1 in 
NCAM+/– mice was less pronounced when compared with NCAM–/– mice. In 
the NCAM+/– mice, the level of phosphorylated FGFR1 was 65–70% of 
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control, whereas in NCAM–/– mice, the level was only 30–35% of control 
levels (100%). 
In both mutant genotypes, the reduction in phosphorylation of the FGF 
receptor was accompanied by an increase in FGF-2 protein in hippocampal 
tissues. Recently, it was shown that alteration in hippocampal FGF-2 expression 
may represent a key mechanism in the genesis of anxiety disorders (Turner et 
al., 2011). To date, there is no evidence showing that NCAM directly affects the 
expression of FGF-2. The observed increase in growth factor protein in our data 
is likely a compensatory reaction due to the reduced FGF-mediated signalling. 
These data suggest important permissive roles of NCAM in FGF-mediated 
signalling because in NCAM deficient mice, an increase in FGF-2 protein was 
not capable of activating FGFR1. Our data also show that the behavioural 
phenotype due to NCAM deficiency may be dependent on the magnitude of 
FGFR1 phosphorylation. Indeed, the FGF signalling system has diverse 
biological functions during brain development and in adulthood (Powers et al., 
2000). Several recent studies have proposed a link between the FGF system and 
depression (Evans et al., 2004; Gaughran et al., 2006).  
A previous study (Aonurm-Helm et al., 2008) showed reduced levels of 
phosphorylated CREB and pCaMKII and pCaMKIV in the hippocampus of 
NCAM–/– mice and suggested that this dysregulation may underlie the 
observed behavioural phenotype of NCAM–/– mice. In contrast to the  
NCAM–/– mice, the levels of phosphorylated CaMKII and CaMKIV were 
unchanged in NCAM+/– mice. No difference in the phosphorylation level of the 
transcription factor CREB was observed between the NCAM+/– and wild-type 
animals either. It appears that a partial reduction in NCAM proteins does not 
affect the basal activity of CaMKII or CaMKIV signalling pathways.  
There is no doubt that CaMKII and CaMKIV and CREB play critical roles in 
the regulation of neural plasticity and the formation of memory (Lisman, 1994; 
Frankland et al., 2001; reviewed in Lisman et al., 2002 and Carlezon et al., 
2005; Restivo et al., 2009). The roles of these intracellular signalling pathways 
in the mechanisms of mood disorders are less obvious. Some preliminary 
studies have demonstrated decreased levels of CaMKII mRNA in the prefrontal 
cortex of patients with bipolar disorder (Xing et al., 2002). Reduced CREB 
phosphorylation has been found in the brains of patients with major depressive 
disorder (Yamada et al., 2003). A number of studies have shown that the 
activation of CREB and CaMKII is implicated in the actions of antidepressants 
(Popoli et al., 2001; Du et al., 2004; Tiraboschi et al., 2004; Blendy, 2006; 
reviewed in Tardito et al., 2006).  
Thus, our data show that contrary to NCAM–/– mice, the observed be-
havioural phenotype in mice with a partial deficiency in NCAM is not 
associated with alterations in the basal phosphorylation levels of CaMKII and 
CaMKIV or CREB. This behavioural phenotype may be dependent on a partial 
reduction in phosphorylation of the FGF receptor, which might account in part 
for the observed depression-like behaviour in these animals.  
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4. Altered levels of the serotonin-transporter  
in the brains of mice with a partial or complete 
deficiency of the NCAM protein 
Alterations in the serotonergic system have been implicated in depression and 
other mood and anxiety disorders (Caspi et al. 2003; Murphy and Lesch 2008; 
Owens and Nemeroff, 1998). Serotonin is a widespread neurotransmitter in the 
central nervous system. It has been shown that serotonergic cell bodies are 
located in the raphé nuclei of the brain stem, and from there, they project 
numerous axonal fibers to many brain regions, such as cortical areas, the 
hippocampus, and the basal ganglia (Pineyro and Blier, 1999). The most widely 
reported serotonergic abnormality in major depression involves the serotonin 
transporter (Owens and Nemeroff 1998; Mann et al., 2000). The serotonin 
transporter is the main mechanism of removal of serotonin from the synapse, 
thereby maintaining homeostatic levels of serotonin in the extracellular space 
(Blakely et al. 1991; Hariri and Holmes, 2006). Interestingly, calcium and 
calmodulin have likewise been identified as regulators of SERT function by 
altering the affinity of 5HT binding to the SERT (Jayanthi et al., 1994). 
Recently, mutations of the SERT were found to induce alterations in the 
expression of BDNF (Molteni et al., 2010). BDNF is a neurotrophin that is 
involved in the etiopathology of mood disorders and in the mechanism of action 
of antidepressant drugs (Nibuya et al., 1995; Calabrese et al., 2007), and a close 
link between serotonin and BDNF has been suggested (Martinowich and Lu, 
2008). Furthermore, it has been shown that alterations in BDNF can also alter 
serotonergic function (Guiard et al., 2008). There is also a close link between 
BDNF and PSA-NCAM as PSA-NCAM may sensitize neurons to BDNF (Kiss 
et al., 2001; Vutskits et al., 2001). It is also believed that PSA-NCAM binds to 
BDNF resulting in the phosphorylation of its major receptor, tropomyosin-
related kinase B (TrkB) (Brennamann and Maness, 2008). This hypothesis is 
supported by findings that expression of BDNF and TrkB are reduced in the 
hippocampus of depressed individuals and this reduction can be reversed with 
antidepressant treatment (Nibuya et al., 1995).  
Thus, reduced levels of NCAM/PSA-NCAM can lead to alterations in the 
expression of SERT. Future investigations are required to determine the link 
between SERT, BDNF and TrkB in these animals. 
In summary, the observed depression-like phenotype in NCAM+/– or 
NCAM–/– mice may be caused by a reduction in SERT expression. 
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CONCLUSIONS 
1. Our data show that animals with a constitutive complete deficiency of 
NCAM protein demonstrate depression-like behaviour and altered cognitive 
functions. Heterozygous mice with a partial reduction in NCAM protein 
levels demonstrate a depression-like behaviour without alterations in cogni-
tive functions. We conclude that impaired plasticity due to NCAM 
deficiency might induce both memory dysfunction and depression-like state, 
depending on the extent of plasticity impairment. 
 
2. NCAM-deficient mice, under basal conditions, demonstrated significantly 
higher numbers of FosB/FosB-positive cells in the BLA, PFC and FC 
compared with wild-type littermates. Fear conditioning in NCAM–/– mice 
did not induce FosB/FosB expression in these brain structures.  
These data suggest that in NCAM-deficient mice, structures involved in fear 
memory formation are constantly activated and this activation interferes with 
their ability to form new fear-related memories. 
 
3. Our study shows that the anxiolytic-like behaviour of NCAM-deficient mice 
in the EPM is largely related to their inability to recognize and learn the 
danger associated with the open arms.  
 
4. We found that both NCAM+/– and NCAM–/– mice showed reduced phos-
phorylation of the FGFR1 but in contrast to NCAM–/– mice, the observed 
behavioural phenotype in NCAM+/– mice is not associated with alterations 
in the basal phosphorylation levels of CaMKII and CaMKIV or CREB. 
 
5. Partial or complete deficiency of NCAM affects the expression of SERT in 
frontal cortex and hippocampus. We propose that the reduction in SERT may 
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SUMMARY IN ESTONIAN 
Osalise või täieliku NCAM valgu puudulikkusega  
hiirte fenotüüp 
Aju plastilisust saab kirjeldada kui aju omadust adapteerida ning reageerida 
adekvaatselt erinevatele endogeensetele ja välistekkelistele stiimulitele. Sünap-
tiline plastilisus on aju plastilisuse üks oluline osa, mis võimaldab ajul pidevalt 
luua ja eemaldada rakkudevahelisi kontakte. Kognitiivsetele võimetele nagu 
õppimine, mälu, aistingud ja teadvus on oluline pidev aju neuronaalsete võr-
kude muutumine (Purves and Andrews, 1997; Albright et al., 2000). Lisaks on 
leitud, et aju plastilisus, mis hõlmab ka närvikoe erinevaid morfoloogilisi muu-
tusi, on oluline faktor depressiooni välja kujunemisel (Duman, 2009). Neuro-
naalsete rakkude adhesioonimolekul (NCAM) ja tema polüsialüülitud vorm 
(PSA-NCAM) on valgud, mis on üheks peamisteks sünaptilise plastilisuse 
kujundajateks (Kiryushko et al., 2003; Rønn et al, 2000). Eelnevad uuringud 
kinnitavad, et NCAM molekulid on võimelised seostuma nii omavahel (Gascon 
et al., 2007) kui ka teiste erinevate rakupinna valkudega (Heiland et al., 1998; 
Vutskits et al., 2001; Povlsen et al., 2008). Sellisel moel osaleb NCAM/PSA-
NCAM erinevate signaalradade käivitamises ja regulatsioonis. NCAM/PSA-
NCAM’i üks olulisemaid interakstsioonipartnereid on fibroblastide kasvufaktori 
retseptor 1 (FGFR1, Kiselyov et al., 2003; 2005). NCAM/PSA-NCAM ja 
FGFR1 vastastikuse mõju tulemusena aktiveeritakse signaalrajad, mis oma-
korda mõjutavad differentseeruvate neuronite arengut (Kolkova et al. 2000) ja 
erinevaid FGFR1 vahendatud neuronaalseid funktsioone (Hansen et al., 2010). 
Varasemates töödes on näidatud, et hiirtel, kellel oli täielikult välja lülitatud 
Ncam1 geen täheldati suurenenud ärevust ja vähenenud õppimisvõimet. Sellega 
kaasnes oluliselt langenud FGFR1 aktivatsioon ja ka kaltsium-kalmoduliinist 
sõltuvate kinaaside II ja IV (CaMKII ja IV) ning transkriptsioonifaktori CREB 
aktivatsiooni langus (Aonurm-Helm et al., 2008).  
 
 
Käesoleva töö eesmärgid 
1. Teha kindlaks, kuidas osaline (NCAM+/–) või täielik (NCAM–/–) NCAM/ 
PSA-NCAM’i puudumine hiirtel mõjutab nende fenotüüpi; 
2. Selgitada, kuidas täielik NCAM’i puudumine mõjutab neuronaalset aktiiv-
sust mälu formeerumisega seotud ajupiirkondades; 
3. Selgitada, kas halvenenud kognitiivsed võimed NCAM–/– hiirtel võivad 
mõjutada nende käitumist pluss-puuris; 
4. Selgitada, kuidas osaline või täielik NCAM’i puudumine mõjutab NCAM-
vahendatud signaalradu; 
5. Uurida, kas NCAM’i puudulikkus mõjutab serotonergilise süsteemi üht olu-
list komponenti – serotoniini transporterit. 
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Töö tulemused ja järeldused 
Antud töö tulemused kinnitasid, et NCAM–/– hiirtel esines depressioonisarnane 
käitumine ning olid vähenenud kognitiivsed võimed. NCAM+/– hiirtel esines 
samuti depressioonisarnane käitumine, kuid nende kognitiivsed võimed ei olnud 
kontrollhiirtega võrreldes muutunud. Ühtlasi ilmnes, et ajupiirkonnad, mis on 
olulised hirmumälu tekkeks, olid NCAM–/– hiirtel püsivalt aktiveeritud ning 
see hüperaktiivsus võib olla ka mäluhäirete tekke üheks põhjuseks. Selgus, et 
vähenenud ärevuskäitumine pluss-puuris oli seotud NCAM–/– hiirte halve-
nenud kognitiivsete võimetega kuna nad ei olnud võimelised õppima ja adek-
vaatselt hindama avatud haarale minemisega seotud ohtu. NCAM+/– hiirtel 
leidsime, et ka nendel oli hipokampuse piirkonnas langenud FGFR1 aktivat-
sioon, mis võibki olla nende loomade käitumusliku fenotüübi põhjus. Kuid 
erinevalt NCAM–/– hiirtest ei kaasnenud NCAM+/– hiirtel FGFR1 aktivat-
siooni langusega CaMKII ja CaMKIV ning CREB aktivatsiooni muutust. 
Ühtlasi leidsime, et NCAM puudulikkus mõjutab serotoniini transporteri eks-
pressiooni. Võib oletada, et just vähenenud serotoniini transporteri ekspressioon 
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